We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| YM Bio. Com Shs | YMBA | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 75.00 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 75.00 | 75.00 |
| Top Posts |
|---|
Posted at 21/1/2007 23:07 by rambutan2 TORONTO (Dow Jones)--Versant Partners has chosen five companies as its top picks for 2007, attaching its highest "strong buy" rating to one of the five and "buy" ratings to the remaining four. Versant's top picks for the year are: Allen Vanguard Corp. (VRS.T) -Rated strong buy, with a C$10.50 target. -A seven-year agreement with Lockheed Martin Corp. (LMT) for Electronic Counter Measures products to be used by the U.S. military is expected to result in additional orders in 2007. Versant notes the U.S military has budgeted to spend more than $1.4B on ECM this fiscal year. -Allen Vanguard is off 2% at C$3.75 in Toronto. Jazz Air Income Fund (JAZ.UN.T) -Rated buy, with a C$10.60 target. -Despite trusts losing favor with investors in late 2006, Versant said a long-term capacity purchase agreement with Air Canada (AC.A.T) guarantees Jazz Air's revenue and earnings stream at aset margin and allows any uncontrollable costs to pass through to Air Canada. -Jazz Air is up 1.2% at C$8.35 in Toronto. Matrkion Inc. (MTK.T) -Rated buy, with a C$4.50 target -With many of its previous top picks moving close to "fair value," Versant now favors Matrkion from a risk/reward standpoint, noting it has yet to make a "significant" move. Versant believes the company will continue to leverage plant deployments into corporate-wide deals. -Matrikon is off 1.5% at C$3.35 in Toronto. Transition Therapeutics Inc. (TTH.T) -Rated buy, with a C$3 target. -Transition has a diversified project pipeline, but Versant notes the main value drivers are its Islet Cell Neogenesis Therapy program in diabetes and its small molecule Alzheimer's diease program. Versant said both projects have "blockbuster" potential. -Transition is off 2.8% at C$1.40 in Toronto. YM Biosciences Inc. (YMI) -Rated buy, with a C$10 target. -Approvable data is expected from co.'s lead breast cancer drug tesmilifene by mid-2007. Versant also sees upside from co.'s TharaCIM antibody drug in multiple cancer markets. -YM is up 2% at C$3.40 in Toronto. |
Posted at 09/3/2006 01:48 by rambutan2 few snippet of conversation from 03/03/06 stateside, where tradeable options on ym have just been made available...Over $1 million was bet today that YMI will be over $9 by October. The average call sold for $1.50, expiring in Oct for a $7.50 strike. The sell side was willing to take the $1.50 plus the possible $7.50 to receive $9 for stock they probably paid $4.25 for. Nice gain. The buy side thinks the stock will be sufficiently higher than $9 to risk $1 million aggregate by October. Wow. (I was a writer of some of the puts today, the $5 strike July and October. If the results are delayed or poor, I'll have the stock put to me at around $3.30 to $3.50 net. That's an OK bet I think.) Let me clarify that last post. I don't think it's amazing that the price would be over $9 at the tesmilifene announcement. I think it's amazing that such large bets were placed on the options expiring in July at the higher strike price. That is confidence that the news will be released when YMI said it would and that the news will be good and that the market will respond at a price sufficiently higher than $9 to make it a worthwhile bet to risk well over $1 million. I prefer to just own the stock. however... the biggest bet today was the sell (at bid and below, $0.85 - 1.05 at 1.24PM) of 5000 contracts (ie 500k (!) shares) of 7.5 Jul calls; someone bets huge money this stock will be below 7.5 by July, or it's someone with big stock position, 50k shares or more, covering (personally, i don't believe that) but... Even if the stock is over $7.50, that seller will receive around $8.50 per share with the option premium. If they were one of the $4.25 secondary offering investors, that's a pretty good rate of return for a few months. Maybe they don't expect results by the July expiration date. |
Posted at 22/2/2006 22:27 by rambutan2 did bode well - up another 6% in states today to close at $5.48 (£3.14). i suspect that the more it becomes visible to the stateside investor the more it is being recognised as way undervalued compared to peers and that the climb will continue. although of course bad news from the tesmilifene phase III would bring things to a juddering halt. |
Posted at 14/2/2006 14:47 by rambutan2 no complaints at $4.25 ie £2.45...YM BioSciences raises US $ 40 million Tuesday February 14, 9:31 am ET MISSISSAUGA, Canada, Feb. 14 /PRNewswire-FirstCal The funds will be used principally to fund YM's drug development activities and for general corporate purposes. Subscribers for the issue included leading health care institutional investors led by Great Point Partners, LLC The transaction is expected to close on or about February 17, 2006, pending stock exchange approval. |
Posted at 09/2/2006 10:03 by rambutan2 mms on the ball here now and opened it at 240-260p.what a stonking looking chart we've now got. that piece in business week has attracted plenty of attention in the states. on robtv last night a bio analyst talked about ym and gave it "star buy" status... 6:00 PM ET Stars & Dogs Investors and the Nortel Settlement; Going Fishing for Biotech Bargains; Andy's Flying an Airline Dog Douglas Loe, healthcare and biotech analyst, Versant Partners Duration: 27 m 32 s |
Posted at 30/1/2006 01:44 by rambutan2 serratia, re ot:has had some heavyweight vc backing. but bio listings have had a tendency to drop after coming to mkt, so will leave alone for time being. re ymba summary. have just tried but failed to do a quick sum up. just doesn't work beyond a v basic view that mkt cap is too small for co with a phase III cancer drug, with lower failure risk than usual, reporting first results mid 06 and with fda permission to finish there and then if they good enough. beyond that it has a v interesting cuban developed humanized, EGF receptor-targeting monoclonal antibody, called nimotuzumab, which is in various trials around the world. they are also have a cancer pain drug which is in trials. etc etc etc etc... to my mind the mkt cap doesn't reflect any of this fully and therefore offers the chance for the shareprice to multiply on favourable results/investor recognition. sorry, there's no way round it, you need to carefully go through their website and the other sources to try and get ones head round it. |
Posted at 14/5/2005 19:28 by rambutan2 Stanford: Buy Target $6.00 (us$ that is)Initiates coverage. Firm believes that investors are not fully aware of potential of Tesmilifene and TheraCIM offers several advantages over Erbitux and ABX-EGF per Briefing.com on 5/05. couple of worth noting posts from states... by: RANDYCHUB (39/M/Wisconsin) Long-Term Sentiment: Strong Buy 05/13/05 11:59 am Msg: 816 of 829 I disagree about the burn rate. We have the cash at the present rate to get tesmilifene thru this phase 3 trial which is key. We also may get theracim brain trials thru phase 3 with oncoscience. by: reid_4 Long-Term Sentiment: Strong Buy 05/13/05 12:41 pm Msg: 818 of 829 Randy -- actually it's a close call. The company says that its cash will be sufficient through fiscal 06, which would mean the end of second quarter 06 (June 30). My opinion is that the company will not want to put itself in the position of possibly running out of money before getting positive results from the Tesmilifene or TheraCim trials. I'd be shocked if they didn't do one more offering before the end of this year or soon thereafter. That is the only reason I can see why the stock price is so depressed. Right now, were talking about a market cap of $80 million for two outstanding very late stage cancer drugs and a third pain drug with substantial promise. TheraCim looks like a no-brainer for approval. The results have been consistently strong, and it's already approved in several countries. Tesmilifene has to repeat what it did with resounding statistical significance in the last phase 3. There's a measure of doubt there, but the chances to me look pretty good that it will. Both of these drugs have blockbuster potential and can be on the market within two years. Someone may want to steal some more shares at absurdly low levels before this stock begins its inevitable march up. |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
